Karen Knudsen, Chief Executive Officer and Executive Director of Parker Institute for Cancer Immunotherapy, shared on LinkedIn:
“Well this is awesome – super charged T-cells! Brilliant advance just reported by Dr. Carnevale and colleagues at PICI Gladstone Institutes + PICI University of California, San Francisco on identifying genetic changes that help T-cells reach tumors, resist suppression, and improve tumor control in pre-clinical models. Next stop, translation?”
Title: In vivo genome-wide CRISPR screens of’ human Tcells in solid tumours
Authors: Qi Liu, Peixin Amy Chen, Esha Urs, Shimin Zhang, Maya M. Arce, Charlotte H. Wang, Jun Yan, Vinh Q. Nguyen, Zhongmei Li, Jin Seo, Nupura Kale, Fanglue Peng, Yikai Luo, Laine Goudy, Taylor N. LaFlam, Haixia Zhong, Chandrima Modak, Emma Dann, Jae Hyung Jung, Amanda Kirane, Allison Betof Warner, Boi Bryant Quach, Zinaida Good, Brian R. Shy, Eric Shifrut, Sagar P. Bapat, Greg M. Allen, Justin Eyquem, Katherine Fuh, Stacie E. Dodgson, Jason G. Cyster, Alexander Marson, and Julia Carnevale
You can also read: Karen Knudsen’s Exclusive Commentary on the New Moderna Cancer Vaccine
